Accueil / Formation Recherche / Publications / Publications Amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales

Publications Amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.


Comprehensive molecular characterization of a heavy chain deposition disease case.


Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury.


Animal models of monoclonal immunoglobulin-related renal diseases.

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. Bridoux F et al. JAMA. 2017 Dec 5.

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants. Garnier C et al. Blood. 2017 Dec 21.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Dimopoulos M et al. J Clin Oncol. 2018 Feb 2.

[Classification and therapeutic management of monoclonal gammopathies of renal significance]. Javaugue V et al. Rev Med Interne. 2018 Mar.

Animal models of monoclonal immunoglobulin-related renal diseases. Sirac C et al. Nat Rev Nephrol. 2018 Apr.

Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. Deshayes S et al. Clin Rheumatol. 2018 Apr.

Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury. Hudier L et al. Clin Kidney J. 2018 Apr.

Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Sanchorawala V et al. Blood. 2017 Aug 3;130(5):597-605.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Palladini G et al. Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743.

Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of
dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F et al. Eur J Cancer. 2017
May;76:183-187.

Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Mohty D et al. Clin Res Cardiol. 2017 May;106(5):331-340.

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Chauvet S et al. Blood 2017
 
The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Vignon M et al. Kidney Int 2017
 
Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Bridoux F et al. Kidney Int. 2017
 
Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Vignon M et al. Leukemia. 2017

ACTUALITÉS

Le Pr Eric Oksenhendler récompensé "Médecin de l'année 2018" pour son travail sur la maladie de Castleman

Calendrier 2019 de la filière MaRIH disponible !
Téléchargez le nouveau calendrier avec les dates de la filière, des centres de référence, des associations de patients et des sociétés savantes
Nouveau cas clinique "Amylose AL"
Testez vos connaissances
Voir toutes les actualités

AGENDA

Du 24-01-2019 au 25-01-2019 : Congrès de la Société d'Hématologie et d'Immunologie Pédiatrique, Chamonix


25-01-2019 : 5ème Journée Maladies Rares Hématologie - Médecine Interne, Paris


01-02-2019 : Journée annuelle du centre de référence de l'amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales, Paris
Voir tout l'agenda